[HTML][HTML] Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure

DH Kang, J Lee, S Im, C Chung - Cancers, 2024 - mdpi.com
Background: The persistence of chemotherapy-resistant and dormant cancer cells remains a
critical challenge in the treatment of lung cancer. Objectives: This review focuses on non …

β-glucan combined with Envafolimab and Endostar as immune rechallenge for metastatic non-small cell lung cancer

Q Geng, Y Lu, D Li, L Qin, C Qi, X Pu, Y Zhuang, Y Zhu… - BMC immunology, 2024 - Springer
Background Immune checkpoint inhibitor rechallenge has emerged as a prominent study
area in non-small cell lung cancer (NSCLC). β-glucan was reported to reverse resistance to …

[HTML][HTML] Predictive markers of response to immune checkpoint inhibitor rechallenge in metastatic non-small cell lung cancer

AA Musaelyan, SV Odintsova… - … of Targeted Anti …, 2024 - pmc.ncbi.nlm.nih.gov
Aim: The present study aims to evaluate the efficacy of rechallenge with immune checkpoint
inhibitors (ICIs) compared to chemotherapy and the predictive role of clinical parameters in …

Tumor Cell-Intrinsic Circular RNA CircFNDC3B Attenuates CD8+ T Cells Infiltration in Non-Small Cell Lung Cancer

Z Qiong, X Xuan, Q Yue, C Long, J Ke - 2024 - researchsquare.com
Tumor-infiltrating CD8+ T cells are related with a satisfactory immunotherapy efficacy and a
survival benefit. However, the mechanisms underlying differential infiltration levels are …